Stockscreener 앱 받기
20.52
3.21%
-0.68
전일 마감가:
$21.20
열려 있는:
$21.2
하루 거래량:
1.62M
Relative Volume:
0.61
시가총액:
$2.60B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-10.16
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
+0.29%
1개월 성능:
+30.62%
6개월 성능:
+65.89%
1년 성능:
+35.98%
1일 변동 폭
$20.39
$21.35
1주일 범위
$18.41
$21.50
52주 변동 폭
$6.78
$21.50
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
20.52 | 2.68B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
222.21 | 35.99B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
70.33 | 12.26B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
41.26 | 7.73B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
85.37 | 7.43B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
39.20 | 7.14B | 11.99B | 24.18M | 234.31M | 0.2956 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
Sumitomo Mitsui Trust Group Inc. Sells 636,744 Shares of 10x Genomics $TXG - MarketBeat
Aug Weekly: Whats the fair value of AN2 Therapeutics Inc stockWeekly Investment Summary & Technical Pattern Alert System - baoquankhu1.vn
Wall Street Recap: What is INTA s revenue forecastTrade Performance Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Insider Trends: Will 10x Genomics Inc outperform its industry peersJuly 2025 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at Valuation Challenges Amidst Sector Potential - DirectorsTalk Interviews
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling - BioSpace
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
10x Genomics (NASDAQ:TXG) Shares Down 8.5%What's Next? - MarketBeat
Cancer Research Institute Launches Transformative AI-Driven Immu - GuruFocus
10x Genomics partners with Dana-Farber to research cancer treatment responses - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research - Investing.com
10x Genomics partners with Brigham & Women’s for autoimmune research By Investing.com - Investing.com Canada
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - Chartmill
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology - PR Newswire
10x Genomics (TXG) Sees Modest Q4 Growth Amid Revenue Challenges - GuruFocus
10x Genomics sees uptick in Q4 revenue despite softer FY sales (TXG:NASDAQ) - Seeking Alpha
10x Genomics (TXG) Achieves Remarkable Progress Despite Economic Challenges - GuruFocus
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results - The Malaysian Reserve
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results | TXG Stock News - Longbridge
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 32% - 富途牛牛
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN
Aug Swings: Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Will 10x Genomics Inc. stock split attract more investorsJuly 2025 Highlights & Verified Swing Trading Watchlist - Улправда
10x Genomics (NASDAQ:TXG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Published on: 2026-01-10 18:33:58 - moha.gov.vn
10x Genomics (NASDAQ:TXG) Reaches New 12-Month HighShould You Buy? - MarketBeat
10X Genomics stock hits 52-week high at 20.36 USD - Investing.com
10X Genomics stock hits 52-week high at 20.36 USD By Investing.com - Investing.com India
Is 10x Genomics Inc. stock a safe haven asset2025 Market Sentiment & Safe Capital Allocation Plans - ulpravda.ru
Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumWeekly Gains Summary & Reliable Entry Point Alerts - Улправда
What technical charts say about 10x Genomics Inc. stockJuly 2025 Catalysts & Accurate Intraday Trade Tips - ulpravda.ru
Is 10x Genomics Inc. stock oversold or undervalued2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Gains Recap: Why 10x Genomics Inc. stock is favored by top institutionsJuly 2025 Action & Free Fast Entry Momentum Trade Alerts - Улправда
Risk Check: How 10x Genomics Inc. stock benefits from strong dollar2025 Market Trends & Accurate Intraday Trading Signals - ulpravda.ru
Is 10x Genomics Inc. stock safe for conservative investorsValue Stock Picks & Free Wealth Planning Blueprints - Улправда
10x Genomics (TXG) Sees Target Price Increase in Latest Analyst Rating | TXG Stock News - GuruFocus
Why 10x Genomics Inc. stock could outperform in 2025Dividend Aristocrats List & Small Capital Trading Growth - ulpravda.ru
10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response - BioSpace
CareDx, 10x Genomics Establish Multiomics Research Initiative - Contract Pharma
CareDx and 10x Genomics partner on transplant rejection research - Investing.com
CareDx, Inc. and 10x Genomics to Launch ImmuneScapeA Multiomics Research Platform to Decode Transplant Rejection and Drug Response - marketscreener.com
Page not foundFactor Thisâ„¢ - FinancialContent
10x Genomics (TXG) Stock Is Up, What You Need To Know - Finviz
10x Genomics (TXG) Gains as Analysts Raise Price Targets in Early 2026News and Statistics - IndexBox
Financial Consulate Inc. Acquires New Holdings in 10x Genomics $TXG - MarketBeat
Weekly Earnings: Is 10x Genomics Inc 1KJ stock a top pick for value investorsWeekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
S P Trends: How dovish Fed policy supports 10x Genomics Inc 1KJ stockMarket Sentiment Review & Weekly Watchlist of Top Performers - moha.gov.vn
10x Genomics, Inc. (TXG) Stock Analysis: Navigating a Complex Market with a 7.47% Potential Upside - DirectorsTalk Interviews
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Taich Adam | Chief Financial Officer |
Nov 24 '25 |
Sale |
19.00 |
11,888 |
225,852 |
297,385 |
| Hindson Benjamin J. | See Remarks |
Nov 24 '25 |
Sale |
19.00 |
8,283 |
157,363 |
432,605 |
| Saxonov Serge | Chief Executive Officer |
Nov 24 '25 |
Sale |
19.00 |
13,261 |
251,936 |
1,021,556 |
2.26%
2.88%
자본화:
|
볼륨(24시간):